Opendata, web and dolomites

MEXOM SIGNED

Development and characterization of extracellular vesicles an innovative cell-free therapeutical product for treatment of stroke

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MEXOM project word cloud

Explore the words cloud of the MEXOM project. It provides you a very rough idea of what is the project "MEXOM" about.

models    gmp    ex    competences    molecules    action    ischemic    data    failed    stem    he    vivo    clinical    immunomodulatory    transferable    experiments    innovation    regenerative    academia    receive    acute    acquire    transfer    applicable    host    time    unmet    extracellular    assurance    brain    advancing    molecular    communication    fellowship    stakeholders    mechanism    vital    vitro    industry    quality    plays    private    public    msc    mature    indicate    inflammation    world    cord    effect    demonstrated    small    manufacturing    stroke    property    deleterious    mscs    medicine    mesenchymal    preclinical    researcher    exert    preconditioning    treatment    enrichment    cell    glp    biology    cargo    human    clinically    commercial    inflammatory    grade    vesicles    reinforce    evs    scientist    disability    first    boosted    innovations    worldwide    training    candidate    anti    intellectual    regulations    leader    highlight    independent    secreted    cells    career    skills    medical    molecule    policymakers    civil    societies    micrornas    entrepreneurship   

Project "MEXOM" data sheet

The following table provides information about the project.

Coordinator
THE CELL-FACTORY 

Organization address
address: GALILEILAAN 19
city: NIEL
postcode: 2845
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 160˙800 €
 EC max contribution 160˙800 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2018
 Duration (year-month-day) from 2018-09-03   to  2020-09-02

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CELL-FACTORY BE (NIEL) coordinator 160˙800.00

Map

 Project objective

Stroke is leading cause of long-term disability in Europe and worldwide with no effective treatment so far. Inflammation plays a vital role in brain’s response to ischemic stroke with deleterious consequences during early acute phase. Strong immunomodulatory effect of human mesenchymal stem cell (MSCs) demonstrated in many preclinical stroke models, however, has failed in clinical experiments. Recent preclinical data indicate that MSCs exert their anti-inflammatory effects via secreted extracellular vesicles (EVs) through microRNAs and this potential could be boosted by preconditioning MSCs ex vivo with small molecules. The aim of this Fellowship will be the determination of MSC-EVs anti-inflammatory mechanism of action specific for stroke for the first time.

The Host has developed clinical-grade technology (GLP/GMP) for human cord MSC-EVs manufacturing at large scale with anti-inflammatory action. During this Project the Researcher will receive training-through-research and will investigate the small molecule potential impact on MSC-EVs cargo enrichment with specific microRNAs. Then he will study candidate microRNAs anti-inflammatory potential in vitro on the key brain inflammation cells. The Researcher will acquire transferable knowledge in regulations, quality assurance, intellectual property and entrepreneurship. Novel competences will reinforce the Researcher as mature and independent scientist in the field of regenerative medicine with new career opportunities in private sector. Communication and dissemination will be carried out with all stakeholders, including academia, industry, civil societies, policymakers and general public.

The Researcher will transfer his molecular biology knowledge and skills, thus advancing the development of MSC-EVs product for treatment of stroke at the Host towards clinically applicable commercial innovation. This Fellowship will highlight Europe as world leader in innovations targeting unmet medical needs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEXOM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEXOM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MacMeninges (2019)

Control of Central Nervous Sytem inflammation by meningeal macrophages, and its impairment upon aging

Read More  

IMPRESS (2019)

Integrated Modular Power Conversion for Renewable Energy Systems with Storage

Read More  

5G-ACE (2019)

Beyond 5G: 3D Network Modelling for THz-based Ultra-Fast Small Cells

Read More